TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05658575: Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Sponsor: Olatec Therapeutics, Inc. · Phase: PHASE2/PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 300 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,240,930

Rescue Site Savings

+$2,146,590

Unlock Full NCT05658575 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05658575 Rescue Dossier →